Strategic Initiative
Slingshot members are tracking this corporate initiative:
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BLRX |
|
|
||||
Additional Information
The open-label, single center, single-arm Phase 2 study aims to evaluate the potential of BL-8040 with KEYTRUDA in pancreatic cancer and will focus on the mechanism of action by which both drugs might synergize. In addition to assessing clinical response, the study will include multiple assessments to evaluate the biological anti-tumor effects induced by the combination. BioLineRx will supply BL-8040 for the study, which is expected to commence later this year.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Aug 08, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q4, 2016
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Keytruda, Pancreatic Cancer, Bl-8040, Combination Therapy
